Diclofenac poses a cardiovascular risk similar to rofecoxib and should be removed from national Essential Medicines Lists.
May warrant clinician caution with diclofenac; leaves open need for RCTs before Essential Medicines List changes.
Listing of NSAIDs on national EMLs should take account of cardiovascular risk, with preference given to low risk drugs. Diclofenac has a risk very similar to rofecoxib, which was withdrawn from worldwide markets owing to cardiovascular toxicity. Diclofenac should be removed from EMLs.
No takes yet. Share an insight, caveat, or question.
McGettigan et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: